Emergence of the Phosphoinositide 3-Kinase-Akt- Mammalian Target of Rapamycin Axis in Transforming Growth Factor-β-Induced Epithelial-Mesenchymal TransitionLamouille S. · Derynck R.
Departments of Cell and Tissue Biology, and Anatomy, Programs in Cell Biology and Developmental Biology, University of California, San Francisco, Calif., USA Corresponding Author
Dr. Rik Derynck
Department of Cell and Tissue Biology, University of California at San Francisco
513 Parnassus Avenue, Room HSW-613
San Francisco, CA 94143-0512 (USA)
Tel. +1 415 476 7322, Fax +1 415 502 7338, E-Mail firstname.lastname@example.org
During development and in pathological contexts such as fibrosis and cancer progression, epithelial cells can initiate a complex transcriptional reprogramming, accompanied by dramatic morphological changes, in a process named ‘epithelial-mesenchymal transition’ (EMT). In this transition, epithelial cells lose their epithelial characteristics to acquire mesenchymal properties and increased motile and invasive behavior. Transforming growth factor-β (TGF-β) has emerged as a major inducer of EMT through activation of downstream signaling pathways, including Smad and non-Smad signaling pathways. Among the non-Smad pathways, increasing evidence is emerging that the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin axis plays a major role in TGF-β-induced EMT, notably through the regulation of translation and cell invasion. Pharmacological inhibitors of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin pathway may therefore represent an opportunity to selectively target essential aspects of TGF-β-induced EMT and provide an approach to prevent cancer cell dissemination toward metastasis, without the need to fully inactivate TGF-β signaling.
© 2010 S. Karger AG, Basel
During development, in response to injury, inflammation and pathological conditions, epithelial cells show a remarkable differentiation plasticity. A manifestation of this plasticity is the process that has been named ‘epithelial to mesenchymal transformation’ or ‘transdifferentiation’, but is now more commonly referred to as ‘epithelial-mesenchymal transition’ (EMT). In EMT, the loss of epithelial characteristics, such as intercellular contacts and cell polarity, is complemented by the acquisition of mesenchymal characteristics and increased cell motility and invasion (fig. 1). This transition involves a complex transcriptional reprogramming and non-transcriptional signaling events that contribute to major changes in cell morphology and behavior. Depending on the physiological and tissue contexts, cells that have undergone EMT can revert to reacquire their epithelial characteristics, thus leading to a mesenchymal-epithelial transition [Kalluri and Weinberg, 2009]. Over the last 15 years, transforming growth factor-β (TGF-β) has been shown to function as a potent inducer of EMT, with its signaling pathways intimately involved in the activation and progression of EMT [Moustakas and Heldin, 2007; Miyazono, 2009; Xu et al., 2009].
Three types of EMT with distinct functional consequences have been distinguished, depending on the developmental and physiological context [Kalluri and Weinberg, 2009]. Type 1 EMT is linked to developmental processes. During vertebrate embryonic development, EMT occurs in a precise and programmed spatiotemporal manner, starting as early as gastrulation, when it mediates the formation of the mesoderm. EMT is also a key process in the delamination of neural crest cells that disperse to give rise to a variety of cell types, including osteoblasts, chondrocytes and muscle cells. At later stages, an EMT-like process allows endothelial cells to transition into mesenchymal cells, e.g. in heart development. EMT is also involved in the fusion of the palatal shelves and in Müllerian duct regression [Acloque et al., 2009; Thiery et al., 2009]. The 2 other types of EMT are not involved in normal development, but occur in response to injury or inflammation and are at the basis of pathological processes. Type 2 EMT occurs in wound healing, tissue repair and regeneration and is also associated with inflammation-induced fibrosis. Such fibrosis involves a mesenchymal conversion of epithelial cells in addition to an infiltration and proliferation of fibroblasts [Iwano et al., 2002; Kalluri and Neilson, 2003]. Finally, during tumor progression, carcinoma cells can escape the environment of the primary tumor by initiating an EMT process, resulting in motility and invasive behavior which potentially leads to metastasis at distant sites. Once in the new loci, these cancer cells can then revert through mesenchymal-epithelial transition to form metastatic carcinomas. The EMT associated with cancer invasion and progression has been classified as type 3 EMT [Thiery and Sleeman, 2006; Kalluri and Weinberg, 2009; Klymkowsky and Savagner, 2009].
The transition from an epithelial to a mesenchymal phenotype involves dramatic changes in gene expression, as well as in cell morphology and behavior (fig. 1). An early step in EMT is the dissolution of epithelial cell junction complexes that mediate cell-cell adhesion. These specialized junction complexes consist of transmembrane molecules that, through interactions with adaptor proteins beneath the plasma membrane, interact with the actin cytoskeleton, intermediate filaments or microtubules. Among these complexes, tight junctions contain occludin and claudins that bind zonula occludens proteins, adherens junctions are characterized by E-cadherin that binds to β- or p120-catenin, gap junctions contain connexins, and desmosomes consist of desmosal cadherins that bind proteins in the submembranous plaque. The rapid delocalization of these junctional proteins and the downregulation of their expression represent early steps in EMT that lead to the individualization of the cells [Thiery and Sleeman, 2006; Xu et al., 2009]. Concomitantly, the cells lose their apical-basal polarity and epithelial cell architecture. Two polarity complexes, one composed of Par3 and Par6, and the other one comprising Crumbs-3, localize predominantly to tight junctions and are disrupted when the tight junctions are disassembled [Moreno-Bueno et al., 2008]. Accompanying the disassembly of the junction complexes, the cortical actin cytoskeleton is reorganized through the activities of Rho-like GTPases (Rho, Rac and Cdc42) into stress fibers extending within lamellipodia and filopodia. In these stress fiber-enriched protrusions, actin can dynamically polymerize and depolymerize allowing for enhanced cell motility [Zavadil and Böttinger, 2005; Yilmaz and Christofori, 2009].
Since many of the junction complex proteins characterize epithelial cells, the dissolution of the junctions results in a loss of many epithelial marker proteins. Among them, decrease in E-cadherin expression has become a major indication of loss of epithelial characteristics. Further, the expression of other epithelial proteins, such as epithelial-specific cytokeratins, is also downregulated. In EMT, the loss of epithelial markers is accompanied by an induction of the expression of mesenchymal proteins, such as vimentin. In addition, expression of N-cadherin, a mesenchymal protein that promotes migration and invasion, increases while the expression of E-cadherin decreases. EMT is also marked by increased expression of matrix metalloproteinases, which degrade extracellular matrix, and extracellular matrix proteins such as fibronectin, collagens or laminin [Zavadil and Böttinger, 2005; Zeisberg and Neilson, 2009]. Together, loss of epithelial protein expression, changes in cell shape and expression of mesenchymal proteins result in a motile cell behavior that allows invasion into surrounding tissues with increased extracellular matrix turnover.
The complex changes in gene expression that are at the basis of EMT result largely from the actions of 3 families of transcription factors, i.e. the Snail, ZEB and basic helix-loop-helix (bHLH) families, whose expression and activities are induced upon initiation of EMT [Peinado et al., 2007]. The Snail (Snail1, Snail2 and Snail3) and ZEB (ZEB1 and ZEB2) proteins represent 2 classes of zinc finger transcription factors whose expression increases during EMT and which bind E-box elements in regulatory promoter sequences. Snail1 and Snail2 can recruit corepressors such as histone deacetylases or C-terminal binding proteins, and in this way transcriptionally repress the expression of target genes, such as the gene encoding E-cadherin [Batlle et al., 2000; Cano et al., 2000; Barrallo-Gimeno and Nieto, 2005]. Similarly, the ZEB transcription factors also have the ability to recruit corepressors, such as C-terminal binding protein, and repress E-cadherin transcription [Comijn et al., 2001; Eger et al., 2005]. Together, Snail and ZEB proteins repress the expression of a number of genes encoding tight junction, adherens junction, desmosome and polarity complex proteins. Besides repressing the expression of epithelial markers, these transcription factors also participate in the increased expression of proteins that characterize the mesenchymal phenotype, such as fibronectin, vitronectin, collagen, N-cadherin and matrix metalloproteinases [Peinado et al., 2007]. bHLH transcription factors also play a role in the progression of EMT. Among these, Twist1 and Twist2 dimerize with another type of bHLH proteins, i.e. E-proteins. These heterodimers then bind to DNA and repress the expression of some epithelial genes such as the gene encoding E-cadherin, while activating the expression of some mesenchymal genes [Perez-Moreno et al., 2001; Yang et al., 2004]. Since inhibitor of DNA binding (Id) proteins inhibit the dimerization and function of Twist transcription factors through dominant negative interference, induction of EMT is accompanied by downregulation of Id protein expression [Ruzinova and Benezra, 2003; Perk et al., 2005]. Interestingly, Snail proteins orchestrate the induction of EMT by increasing the expression of ZEB and bHLH factors [Peinado et al., 2007]. A further level of control in the regulation of this transcription network is exerted by microRNAs. Indeed, members of the miR-200 family act as essential regulators of EMT. They were shown to target and repress the expression of ZEB1 and ZEB2, and, accordingly, their expression is downregulated in cells that undergo EMT, thus leading to a decrease in E-cadherin expression [Gregory et al., 2008].
Recent insights have revealed that signaling pathways, including those initiated by TGF-β, regulate the expression and activities of these transcription factors [Moustakas and Heldin, 2007; Xu et al., 2009]. The orchestration of these transcription pathways, in combination with non-transcription signaling responses, allows TGF-β to act as a potent inducer of EMT. Dissecting the mechanisms of the EMT response to TGF-β provides a paradigm for the cellular basis of epithelial plasticity.
A variety of studies have implicated TGF-β as an inducer or essential mediator of EMT in embryonic development, fibrosis and tumorigenesis. For example, during cardiac development, TGF-β1 and TGF-β2 are expressed in the atrioventricular canal and outflow tract tissue at the onset of EMT, permitting the formation of the heart valves [Nakajima et al., 2000]. TGF-β2 null mice present severe cardiac defects with abnormalities in these regions, and inhibition of TGF-β2 blocks EMT in mouse heart explant cultures [Azhar et al., 2003; Mercado-Pimentel and Runyan, 2007]. As another example, TGF-β3 expression is essential for palatal development and fusion. It is expressed at the site and time of fusion of the palatal shelves, when the epithelial cells undergo EMT, and targeted inactivation of the gene encoding TGF-β3 results in a cleft palate that correlates with the absence of EMT [Pelton et al., 1990; Nawshad et al., 2004].
Consistent with its ability to induce a strong fibrotic response when injected subcutaneously, TGF-β acts as a mediator of pathological fibrosis in a variety of tissues including the kidney, liver, lung and heart. While this response involves the attraction and proliferation of fibroblasts in response to TGF-β, increasing evidence is emerging that TGF-β is also involved in EMT leading to fibrosis. Accordingly, in mouse models and human patients, TGF-β1 expression is increased in chronic kidney disease prior to fibrosis [Schnaper et al., 2003]. Patients with liver disease progressing to hepatic fibrosis also show increased TGF-β1 expression in biliary epithelial cells, and increased TGF-β1 expression occurs in a mouse model of induced liver fibrosis, while blocking TGF-β1 signaling demonstrated significant antifibrotic effect in the liver [Gressner et al., 2002; Meindl-Beinker and Dooley, 2008]. Fibroblasts isolated from patients with pulmonary fibrosis show increased secretion of TGF-β resulting in hyperactive TGF-β signaling [Willis and Borok, 2007]. Further, lineage-tracing experiments in mouse models illustrate a role of EMT of alveolar epithelial cells in lung fibrosis. In the adult heart, an endothelial to mesenchymal transition process occurs in cardiac fibrosis. This process is controlled by TGF-β, and progression of cardiac fibrosis is inhibited in transgenic mice with impaired TGF-β signaling [Zeisberg et al., 2007]. These in vivo observations are complemented by cell culture experiments showing that TGF-β induces EMT in renal tubular epithelial cells, hepatic stellate cells and alveolar epithelial cells, as well as initiating endothelial to mesenchymal transition in endothelial cells [Gressner et al., 2002; Zeisberg et al., 2003; Willis and Borok, 2007; Zeisberg et al., 2007].
TGF-β-induced EMT may also play an important role in carcinoma progression. EMT is thought to be a prerequisite for the invasive behavior of carcinoma cells, leading to dissemination and metastasis [Thiery, 2003; Thiery and Sleeman, 2006; Kalluri and Weinberg, 2009]. Such a role for TGF-β is consistent with the increased production and activation of TGF-β by cancer cells and has been well validated by cell culture and mouse model studies [Bierie and Moses, 2006a]. In addition, in vivostudies confirmed a correlation between the conversion of squamous into more invasive spindle cell carcinomas and the expression of activated TGF-β1 [Cui et al., 1996; Portella et al., 1998; Akhurst, 2008]. Moreover, the increase in TGF-β expression and/or activity provides an advantage for tumor progression not only by inducing EMT, but also by creating an immunosuppressive environment and initiating angiogenesis [Padua and Massagué, 2009]. How important EMT, and more specifically TGF-β-induced EMT, is in human carcinoma progression, invasion and metastasis remains unclear. Nevertheless, research on the molecular mechanisms and the role of TGF-β in EMT and cancer progression has been greatly aided by the characterization of cell culture models for TGF-β-induced EMT. Among these, the normal murine mammary gland (NMuMG) epithelial cell line is perhaps the best studied cell system. In these cells, addition of TGF-β induces an EMT program in cell culture that is completed in 36 h [Miettinen et al., 1994].
Other members of the TGF-β family are also involved in regulating EMT events during development and in cancer, although the knowledge of their roles is currently poorly developed. Bone morphogenetic proteins are involved in EMT processes during gastrulation, neural crest delamination and atrioventricular cushion patterning [Kishigami and Mishina, 2005; Ma et al., 2005; Acloque et al., 2009], and the anti-Müllerian hormone is required for the second phase of Müllerian duct regression [Klattig and Englert, 2007]. In the pathological context, bone morphogenetic proteins have been linked to EMT and invasiveness of several types of cancer cells [Theriault et al., 2007; Gordon et al., 2009], while in other cases, they promote or may be involved in mesenchymal-epithelial transition [Zeisberg et al., 2005].
Discussion of the role of these members of the TGF-β family in EMT is beyond the scope of this overview.
TGF-β signals through a heterotetrameric complex of two TGF-β type II (TβRII) and two TGF-β type I (TβRI) transmembrane dual specificity kinase receptors. Upon TGF-β binding to the receptors, TβRII activates TβRI, which in turn phosphorylates and activates the intracellular mediators Smad2 and Smad3. Once activated, Smad2 and/or Smad3 dissociate from the receptor complex and combine with the common Smad, Smad4, to form trimeric complexes of Smad proteins. These translocate to the nucleus where they cooperate with other transcription factors, coactivators or corepressors, to regulate gene transcription (fig. 2). The inhibitory Smad6 and Smad7 block the activation of Smad2 and Smad3 by preventing their interaction with TβRI. They do not serve as transcription activators, yet may function as transcription repressors [Shi and Massagué, 2003; Feng and Derynck, 2005]. Consistent with the role of TGF-β as inducer of EMT, these receptors and Smads were shown to play a role in EMT.
Expression of a cytoplasmically truncated TβRII has been shown to block TGF-β-induced EMT in normal and cancer epithelial cells through dominant negative interference both in vitro and in vivo [Oft et al., 1998; Portella et al., 1998; Han et al., 2005]. In NMuMG cells, expression of a cytoplasmically truncated TβRI similarly inhibits TGF-β-induced EMT, whereas a constitutively active mutant of TβRI induces EMT in the absence of added TGF-β [Piek et al., 1999; Valcourt et al., 2005]. Similar to the effect of the dominant negative form of TβRI, a pharmacological inhibitor that represses the kinase activity of TβRI prevents TGF-β-induced EMT [Kondo et al., 2004; Lamouille and Derynck, 2007]. Downstream of the receptors, the Smad effectors mediate gene expression responses that are required for the induction of EMT upon TGF-β stimulation [Akhurst, 2008]. Indeed, expression of Smad2, Smad3 and Smad4 mutants that can interfere with Smad function, or downregulation of Smad4 expression using RNA interference, was also shown to inhibit the conversion from an epithelial to a mesenchymal phenotype [Valcourt et al., 2005; Deckers et al., 2006]. However, in some cell contexts, Smad2 was reported to act as an antagonist in TGF-β-induced EMT. For example, Smad2-deficient keratinocytes undergo EMT and promote skin tumor formation through enhanced activities of Smad3 and Smad4 [Hoot et al., 2008; see also Masszi and Kapus, 2011, this issue]. Finally, increased expression of the inhibitory Smad7 represses TGF-β-induced EMT in various epithelial cells [Valcourt et al., 2005; Zavadil and Böttinger, 2005].
The induction of EMT in response to TGF-β has been attributed in part to the Smad transcription complexes that regulate transcription of essential genes involved in this process. Notably, TGF-β signaling directly activates the expression of Snail proteins through Smads. Smad3 binds to regulatory promoter sequences of the gene encoding Snail1 and activates its transcription [Cho et al., 2007; Hoot et al., 2008]. In addition, Smad3 and Smad4 form a complex with Snail1 that binds to E-box and Smad-binding elements in the promoters of the genes encoding E-cadherin, occludin and the tight junction-associated cell adhesion molecule CAR, consequently repressing their transcription [Vincent et al., 2009]. In cells induced to undergo EMT, TGF-β also activates the expression of ZEB transcription factors through upregulation of the expression of the transcription factor Ets1, which then may cooperate with the bHLH transcription factor E47 [Shirakihara et al., 2007]. Moreover, the expression of the miR-200 microRNAs is downregulated in TGF-β-induced EMT, resulting in an increase in translation of the ZEB1 and ZEB2 mRNAs [Gregory et al., 2008]. In addition, expression of ZEB1 and ZEB2 directly represses the transcription of the miR-200 family through binding to ZEB-type E-box motifs in a compact region of the miR-200 family promoter [Bracken et al., 2008; Burk et al., 2008]. TGF-β signaling also regulates the activities of the bHLH family of transcription factors during EMT by repressing the expression of Id factors. In the case of Id1, a complex formed by Smad3, Smad4 and the transcription repressor ATF3, binds sequences in the Id1 promoter and represses its transcription [Kang et al., 2003]. The decrease in expression of Id factors then increases activity of E-proteins and Twist, resulting in transcriptional repression of the E-cadherin gene. Finally, the transcription factor HMGA2, whose expression increases during TGF-β-induced EMT through a Smad3/Smad4-dependent mechanism, has also emerged as an essential mediator in TGF-β-induced EMT by enhancing the expression of Snail and Twist proteins, and by repressing the expression of Id2 [Thuault et al., 2006].
In addition to Smad signaling, which directly targets transcriptional regulation, TGF-β initiates non-Smad signaling pathways (fig. 2) [Derynck and Zhang, 2003; Moustakas and Heldin, 2005]. These pathways include the 3 mitogen-activated protein (MAP) kinase pathways that lead to activation of extracellular-regulated kinase (Erk), p38 and JNK. However, these pathways are generally more prominently activated by tyrosine kinase receptors, principally in response to growth factor stimulation. Activation of these pathways complements the Smad signaling responses to regulate essential aspects of TGF-β-induced EMT, such as cytoskeleton reorganization, and cell migration and invasion. Their synergy with TGF-β/Smad signaling in inducing EMT has been well illustrated through the cooperation of tyrosine kinase receptor activation with TGF-β signaling. For example, epidermal growth factor stimulates Ras and Erk MAP kinase signaling, which enhances TGF-β-induced EMT responses such as repression of E-cadherin expression and activation of Snail2, N-cadherin and matrix metalloproteinase expression [Grande et al., 2002; Schmidt et al., 2005; Uttamsingh et al., 2008]. Accordingly, pharmacological inhibition of MEK proteins, which activate Erk MAP kinase, prevents the EMT process induced by TGF-β [Xie et al., 2004]. Chemical inhibitors of p38 MAP kinase or JNK MAP kinase, and antisense oligonucleotides targeting JNK, have also been reported to block TGF-β-induced EMT as observed with morphological changes and epithelial versus mesenchymal marker regulation [Bakin et al., 2002; Yu et al., 2002; Santibanez, 2006; Alcorn et al., 2008].
TGF-β activates the Ras-Raf-MEK-Erk MAP kinase pathway through the association of ShcA with the TGF-β receptor complex and direct serine and threonine phosphorylation of ShcA by TβRI in response to TGF-β. The phosphorylated tyrosines on ShcA provide a docking site for the recruitment of Grb2 and Sos, and this complex initiates Ras activation leading to Erk MAP kinase signaling cascade [Lee et al., 2007]. TGF-β has been shown to induce p38 and JNK MAP kinase signaling through activation of TAK1 by the ubiquitin ligase TRAF6 that interacts with the TGF-β receptor complex [Sorrentino et al., 2008; Yamashita et al., 2008]. The recent characterization of how these MAP kinase pathways are activated in response to TGF-β should enable a dissection of their relative contributions to TGF-β-induced EMT.
TGF-β also regulates the activity of the small GTPase proteins Rho, Rac and Cdc42, which function as key signaling mediators in the reorganization of the actin cytoskeleton and the formation of lamellipodia and filopodia, actin protrusions that are required for cell migration [Bhowmick et al., 2001; Zavadil and Böttinger, 2005; Yilmaz and Christofori, 2009]. The mechanisms underlying regulation of the small GTPases by TGF-β receptor activation remain poorly characterized. In the early stage of TGF-β-induced EMT, the polarity molecule Par6 interacts at tight junctions with TβRI, and the phosphorylation of TβRI by TβRII recruits the E3 ubiquitin ligase Smurf1 which mediates the ubiquitination and consequently the degradation of RhoA during tight junction disruption [Ozdamar et al., 2005]. In addition, the microRNA miR-155 that targets RhoA expression is upregulated in TGF-β-induced EMT [Kong et al., 2008]. However, during EMT, TGF-β also activates RhoA and its downstream targets rho-associated coiled-coil containing protein kinase (ROCK) and LIM kinase, mediators of actin stress fiber formation [Vardouli et al., 2005; Pellegrin and Mellor, 2007]. Indeed, antisense oligonucleotides that downregulate the expression of ROCK or LIM kinase, and pharmacological inhibition of ROCK, inhibit the actin reorganization that accompanies TGF-β-induced EMT [Bhowmick et al., 2001; Tavares et al., 2006; Cho and Yoo, 2007].
Finally, TGF-β induces Akt activation through phosphoinositide 3 (PI3) kinase during EMT [Bakin et al., 2000; Lamouille and Derynck, 2007]. Once activated, Akt initiates signaling pathways such as the mammalian target of rapamycin (mTOR) pathway, that play roles in cell survival, growth, migration and invasion. The essential role of TGF-β-induced PI3 kinase-Akt-mTOR signaling in the context of EMT is discussed in the remainder of this review.
A variety of tyrosine kinase receptors for growth factors, such as epidermal growth factor, fibroblast growth factor, insulin-like growth factor-1 and insulin, activate signaling through the PI3 kinase-Akt pathway. Moreover, activation of PI3 kinase and Akt signaling has been detected in cells undergoing EMT [Larue and Bellacosa, 2005]. We and others have observed that TGF-β induces the PI3 kinase-Akt pathway in various cell types, including cells that undergo TGF-β-induced EMT [Bakin et al., 2000; Lee et al., 2004; Lien et al., 2006; Rodriguez-Barbero et al., 2006; Lamouille and Derynck, 2007; Lin et al., 2007; Yeh et al., 2008]. These observations raise the question as to what role the activation of PI3 kinase-Akt signaling plays in TGF-β-induced EMT.
Activation of PI3 kinase results in the generation of phosphatidylinositol (3,4,5)-triphosphate (PIP3), which provides a phospholipid binding site for proteins that contain a pleckstrin homology domain, such as Akt. Once Akt is recruited to the plasma membrane, it is fully activated upon phosphorylation on a threonine by the kinase PDK1, and on a serine principally by mTOR in mTOR complex 2 (mTORC2). In some cell models, Akt may also be activated by integrin-linked kinase, a cytoplasmic kinase that relays signals between integrins and the actin cytoskeleton, and integrin-linked kinase function may be required for EMT [McDonald et al., 2008]. The 3 Akt kinases in mammalian cells (Akt1, Akt2 and Akt3) can phosphorylate a range of proteins that regulate physiological processes such as cell survival, growth, metabolism and migration. However, these Akt proteins display distinct functions, based on gene targeting studies [Gonzalez and McGraw, 2009]. In cell culture, downregulation of Akt2 expression blocks the phenotypical changes and cell migration increase that accompany insulin-like growth factor-1-dependent EMT, while downregulating Akt1 expression enhances this effect [Irie et al., 2005]. In the same epithelial cell model, decreased Akt1 expression promotes TGF-β-induced EMT through a decrease in abundance of the miR-200 family [Iliopoulos et al., 2009]. Interestingly, TGF-β2 selectively activates Akt2 but not Akt1 in NMuMG cells [Chaudhury et al., 2010]. However, the role of Akt in EMT, cell migration and invasion may differ depending on the TGF-β isoform and cell model used.
A downstream target of Akt proteins is glycogen synthase kinase-3β (GSK-3β), a kinase that binds to and phosphorylates Snail1, resulting in enhanced cytoplasmic retention and degradation of Snail1. Phosphorylation of GSK-3β by Akt results in its ubiquitination and degradation, leading to increased accumulation of Snail1 in the nucleus and repression of E-cadherin expression, consequently inducing EMT [Zhou et al., 2004; Bachelder et al., 2005]. In addition, Akt induces transcription of the Snail1 gene, through nuclear factor-ĸB activation, in squamous cell carcinoma lines that undergo EMT [Julien et al., 2007]. The nuclear factor-ĸB pathway can also promote EMT, invasion and metastasis in murine mammary cells transformed with H-Ras. Interestingly, interference with nuclear factor-ĸB activity in this cell model prevents TGF-β-induced EMT [Huber et al., 2004]. Akt also phosphorylates TSC2 in the TSC2-TSC1 complex, thus inhibiting its function as GTPase-activating protein toward the small GTPase protein Rheb. As a result, accumulation of Rheb-GTP activates the kinase mTOR in a complex called ‘mTOR complex 1’ (mTORC1) [Laplante and Sabatini, 2009]. Two major kinase targets of mTORC1 have been characterized: S6 kinases and 4E-BP1. The phosphorylation of S6 kinases 1 and 2 by mTORC1 regulates translation initiation and ribosome biogenesis, notably through activation of downstream targets such as the ribosomal protein S6 [Hay and Sonenberg, 2004; Holz et al., 2005]. Phosphorylation of 4E-BP1 by mTORC1 releases the eukaryotic translation initiation factor eIF4E from its interaction with 4E-BP1, thus initiating cap-dependent translation of mRNAs, such as the mRNA for cyclin D1, which is involved in cell cycle progression and proliferation [Hay and Sonenberg, 2004; Robert and Pelletier, 2009]. Therefore, activation of mTORC1 results in enhanced protein synthesis and, consequently, increased cell size. mTORC1 is activated not only in response to growth factors, but also responds to nutrients, amino acids and stress signals [Laplante and Sabatini, 2009].
Besides mTORC1 that comprises mTOR, mLST8 and Raptor, mTOR can also form a complex with mLST8, Rictor, mSin1 and Protor. The biology of this second complex named ‘mTORC2’ is less characterized when compared with mTORC1 [Laplante and Sabatini, 2009]. As mentioned already, mTORC2 mediates Akt phosphorylation, contributing to its full activation [Sarbassov et al., 2005]. It also phosphorylates protein kinase Cα and is believed to regulate the cytoskeletal organization by regulating Rho and Rac activities [Jacinto et al., 2004; Sarbassov et al., 2004]. Rapamycin acts as a specific inhibitor of mTORC1 activity and interferes with the recruitment and activation of mTORC1 targets, possibly by destabilizing the interaction of Raptor with mTOR. Rapamycin does not inhibit the activity of mTORC2, although prolonged rapamycin exposure can decrease mTORC2 activity by destabilizing the assembly of the regulatory components of this complex [Guertin and Sabatini, 2007].
We and others observed that TGF-β induces increases in cell size and protein content in various cell types, including epithelial cells that undergo EMT in response to TGF-β [Lamouille and Derynck, 2007; Das et al., 2008; Wu and Derynck, 2009]. These increases were apparent in 2 models of TGF-β-induced EMT, the murine mammary gland NMuMG cells and the human HaCaT keratinocytes. In these cells, we also detected a TGF-β-induced activation of mTOR resulting in phosphorylation of the 2 targets of mTORC1, S6 kinase 1 and 4E-BP1, through the activation of PI3 kinase and Akt (fig. 3) [Lamouille and Derynck, 2007]. How TGF-β signaling links to activation of PI3 kinase is as yet unclear, although PI3 kinase has been found in association with the activated TGF-β receptor complex [Yi et al., 2005]. The increases in cell size and protein content in response to TGF-β are mediated by the activation of mTORC1, and accordingly, rapamycin inhibits the TGF-β-induced cell size and the protein content increases [Lamouille and Derynck, 2007]. The activation of S6 kinase 1 and 4E-BP1 is most likely responsible for the increased protein synthesis that occurs during TGF-β-induced EMT. These observations demonstrate that TGF-β regulates translation via PI3 kinase, Akt and mTORC1 during EMT. The activation of this translation pathway complements the transcriptional regulation through Smad signaling (fig. 3). Whereas the activation of translation by mTORC1 in response to TGF-β may complement the increased Smad-mediated transcriptional responses, it may also allow for selective translational control of target genes that potentially play a role in the phenotype and behavior of cells that have undergone EMT. Interestingly, increased S6 kinase 1 activity enhances EMT and invasion in human ovarian cancer cells through induction of Snail1 expression at the transcriptional level, but the mechanism of such regulation remains unclear [Pon et al., 2008].
To further define the role of the activation of mTORC1 in TGF-β-induced EMT, we treated NMuMG and HaCaT cells with TGF-β to induce EMT, in the presence of rapamycin. While the cells did not increase in size and protein content, the inhibition of mTORC1 did not block the morphological changes associated with EMT. Accordingly, similar to cells in the absence of rapamycin, TGF-β induced cell shape changes, accompanied with cytoskeletal reorganization, dissolution of the junctions with delocalization of E-cadherin and zona occludens-1, and induction of mesenchymal markers such as fibronectin and N-cadherin. Besides the morphological and gene expression changes, EMT is accompanied by a change in cell behavior, specifically migration and invasion. However, when mTORC1 activity is blocked using rapamycin in cell culture, the cells that have undergone EMT do not show the increases in migration and invasion that normally accompany EMT [Lamouille and Derynck, 2007]. Perhaps the increased protein synthesis that follows mTORC1 activation may participate in the enhanced expression of specific proteins that act directly or indirectly in cell migration and invasion, such as matrix metalloproteinases. Therefore, activation of mTORC1 downstream of PI3 kinase-Akt and in response to TGF-β contributes to EMT in 2 ways. While it mediates the increase in protein synthesis and cell size during EMT, mTORC1 activity is also essential for the increased motility and invasion of cells that have undergone EMT. Since increased invasion plays a key role in cancer progression toward metastasis, these results highlight a role for Akt-mTOR signaling in cancer progression, independent of cell proliferation regulation. Therefore, rapamycin analogs or other inhibitors of mTOR activity may aid in preventing invasion, cancer progression and metastasis. In line with our observations, rapamycin has been found to inhibit the downregulation of E-cadherin expression in mesothelial cells that undergo TGF-β-induced EMT [Aguilera et al., 2005], and to block motility in some other cell models [Liu et al., 2006; Gulati et al., 2009]. On the other hand, the rapamycin-insensitive mTORC2 is believed to play a role in cytoskeleton arrangement through the regulation of Rho, Rac and protein kinase Cα activities [Jacinto et al., 2004; Sarbassov et al., 2004]. Therefore, it is conceivable that this complex could be involved in the process of actin cytoskeleton reorganization that occurs during TGF-β-induced EMT. Interestingly, decreased activity of mTORC2 inhibits the migratory behavior of breast cancer cells [Qiao et al., 2007]. Additional studies will be needed to decipher a possible implication of mTORC2 in EMT and the mechanisms that regulate its activation.
In epithelial cells, TGF-β signaling leads to inhibition of cell proliferation, which serves as an autocrine tumor suppressor function, while other signaling responses can promote the transition toward carcinoma cells and aid in cancer progression. An early event in the transition from epithelial to carcinoma cells is the inactivation of the tumor suppressor effect of TGF-β [Bierie and Moses, 2006b; Nguyen and Massagué, 2007]. Mutations in TβRII and TβRI receptors, as well as in TGF-β Smads, have been observed in carcinomas and inactivate the growth inhibitory activity of TGF-β. In addition, alterations in downstream components of Smad signaling have been shown to result in a similar effect without inactivating other TGF-β responses that are beneficial to the tumor cells [Bierie and Moses, 2006a]. As cancer cells often have increased expression and activation of TGF-β, the autocrine responses of carcinoma cells to TGF-β, in particular the loss of the epithelial phenotype and induction of EMT, are thought to play an important role in driving the invasive behavior of carcinoma cells and progression toward metastasis [Derynck et al., 2001; Nguyen and Massagué, 2007]. Accordingly, expression of dominant negative TβRII receptor in metastatic cell lines inhibits EMT in vitro and in vivo[Oft et al., 1998; Portella et al., 1998; Han et al., 2005]. Therefore, TGF-β-induced EMT correlates with tumor metastasis through an increase in cell-invasive characteristics.
The complexity of the TGF-β signaling responses, and the dual nature of their effects on epithelial cancer cells, i.e. tumor suppression versus cancer progression, has made the development of anti-cancer approaches based on inhibition of TGF-β signaling challenging. Nevertheless, TβRI kinase inhibitors, neutralizing TGF-β antibodies and the dimerized TβRII extracellular domain fused to human IgG Fc domain, are being evaluated in preclinical and clinical trials as inhibitors of cancer progression [Bonafoux and Lee, 2009]. Rather than developing approaches to block all TGF-β signaling and cellular responses, it is preferable to selectively target the TGF-β-induced promotion of invasion and metastasis of cancer cells, thereby avoiding an inactivation of the tumor suppression function of TGF-β. Our insights into the role of Akt-mTOR signaling in TGF-β-induced EMT, and in particular invasion, may provide a basis for such a targeted approach.
Deregulation and increased activities of PI3 kinase and Akt have been linked to tumorigenesis and cancer progression. The gene encoding the catalytic subunit p110α of PI3 kinase is frequently mutated in human tumors, resulting in increased PIP3 production and, consequently, increased Akt signaling. Mutations in the gene encoding the PI3 kinase regulatory subunit p85α have also been identified, and these lead to constitutive PI3 kinase activity [Liu et al., 2009]. Moreover, amplification of Akt genes or overexpression of Akt has been observed in a range of human tumors and is generally associated with poor prognosis. Recently, mutations in the pleckstrin homology domain of Akt1 that lead to growth factor-independent anchoring to the plasma membrane and increased Akt1 phosphorylation have been identified in several cancers [Gonzalez and McGraw, 2009]. Finally, loss of the tumor suppressor PTEN, a phosphatase that antagonizes PI3 kinase activity by dephosphorylating PIP3, is commonly observed in cancer progression [Liu et al., 2009]. These and many other findings link an increase in PI3 kinase and Akt signaling to tumorigenesis and to increased cell survival and decreased apoptosis.
Increased and deregulated mTORC1 and mTORC2 activities have also been observed in tumors and linked to cancer progression. In a tightly controlled manner, mTORC1 regulates the synthesis of proteins involved in cell cycle progression, apoptosis, invasion and angiogenesis. A deregulation of mTORC1-dependent translation initiation consequently allows for enhanced tumor growth and metastasis. Accordingly, increased levels and phosphorylation of downstream targets of mTORC1 have been correlated with tumor aggressiveness in various human malignancies [Guertin and Sabatini, 2007]. In addition, mTORC2 phosphorylates Akt, and this phosphorylation, together with the phosphorylation of Akt by PDK1, results in full Akt activation [Sarbassov et al., 2005]. Although the mechanism of mTORC2 activation requires further characterization, the elevated Akt phosphorylation observed in various human tumors may be explained by a hyperactivation of mTORC2. It has recently been shown that mTORC2 is required for tumor initiation in a model of prostate cancer cells in PTEN-deficient mouse [Guertin et al., 2009].
Because of the frequently observed deregulation in PI3 kinase-Akt-mTOR signaling in human cancers, and its link to increased cell proliferation and survival, the PI3 kinase-Akt-mTOR pathway has been extensively targeted in the development of cancer therapies. Wortmannin and LY294002 represented a first generation of PI3 kinase inhibitors, but their lack of selectivity and high toxicity made these drugs unsuitable for the treatment of cancers. Recently, more isoform-specific chemical inhibitors of PI3 kinase have been developed, with some also targeting the mTOR kinase. For example, PI-103 inhibits the activities of p110α and mTOR, and its use for cancer therapy is being explored [Liu et al., 2009]. With its central role, Akt is also considered an attractive therapeutic target. Accordingly, several Akt inhibitors are currently in clinical trials for cancer treatment. They comprise lipid-based phosphatidylinositol analogs that prevent the localization of Akt to the plasma membrane, ATP-competitive kinase inhibitors and allosteric inhibitors [Liu et al., 2009]. Rapamycin is a natural inhibitor of mTORC1 but its poor solubility led pharmaceutical companies to develop analogs with improved pharmacokinetic properties, some of which are already in clinical use [Guertin and Sabatini, 2009]. Whereas rapamycin inhibits the activity of mTORC1, it does not block the activities of mTORC2, although prolonged exposure to rapamycin can affect the assembly of mTORC2 components [Guertin and Sabatini, 2007]. However, mTORC2 activity has been shown to be enhanced following inhibition of mTORC1, as observed by Akt hyperphosphorylation following rapamycin treatment in several cell models. Therefore, it may be imperative to also target mTORC2. Consequently, pharmacological kinase inhibitors of mTOR that inhibit both mTORC1 and mTORC2 have recently been developed and are clinically evaluated as therapy to cancer progression [Guertin and Sabatini, 2009].
The realization that TGF-β activates signaling through the PI3 kinase-Akt-mTOR axis and that this pathway is required for EMT and invasion now opens several opportunities, yet also leads to new questions. Our current data suggest that, in TGF-β-induced EMT, activation of mTOR signaling is required for motility and invasion, raising the possibility that inhibition of mTOR activity may prevent cancer dissemination. While such an approach may not block the cell morphological changes of EMT, inhibiting the invasion process at the very basis of cancer progression may represent an avenue of selectively inhibiting the cancer-promoting effects of TGF-β without the concern of relieving the tumor suppressor activity of TGF-β. The current findings also raise a number of new questions about the molecular mechanisms and functions associated with TGF-β-induced PI3 kinase-Akt-mTOR signaling. How activation of the TGF-β receptor complex leads to activation of PI3 kinase-Akt-mTOR signaling is currently unclear, nor do we know which PI3 kinase or Akt proteins are involved. Inhibition of mTORC1 represents an attractive approach for the prevention of EMT-associated cell motility and invasion, and in uncovering novel effectors of this process which lie under mTORC1 selective translational regulation. Such a strategy should provide insight into the link between TGF-β-induced EMT and the mechanisms underlying cancer progression.
We are grateful to J. Smyth and J. Xu for their critical review of the manuscript. This research was supported by grants RO1-CA136690 and PO1-HL60231 (project III) to R. Derynck, a postdoctoral fellowship grant (grant 5566-07) from the Leukemia and Lymphoma Society and a scientist development grant (grant 09SDG2280008) from the American Heart Association to S. Lamouille.
Dr. Rik Derynck
Department of Cell and Tissue Biology, University of California at San Francisco
513 Parnassus Avenue, Room HSW-613
San Francisco, CA 94143-0512 (USA)
Tel. +1 415 476 7322, Fax +1 415 502 7338, E-Mail email@example.com
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.